Bioasis Technologies Inc.

As of November 30, 2022, Bioasis Technologies Inc. carries a market capitalization of 9.88M, placing it among publicly traded companies globally. Its enterprise value stands at 11.41M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Bioasis Technologies Inc.'s next confirmed earnings release is scheduled for November 2, 2026.

As of November 30, 2022, Bioasis Technologies Inc. has 79.41M shares outstanding.

These figures are as of November 30, 2022. The price-to-sales ratio is 46.80, and the price-to-book ratio stands at -4.91.

These figures are as of November 30, 2022. The EV/Sales ratio of 56.82 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 11.41M versus a market cap of 9.88M, with the gap driven by net debt and cash on the balance sheet.

As of November 30, 2022, Bioasis Technologies Inc. maintains a current ratio of 0.11, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -82.07, indicating conservative leverage, while an interest coverage ratio of -4.33 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended November 30, 2022. Return on assets (ROA) is negative at -120.62, reflecting losses generated across the asset base.

As of the close on September 28, 2026, Bioasis Technologies Inc.'s stock has declined approximately 50.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.01.

Over the twelve months ended November 30, 2022, Bioasis Technologies Inc. generated 200,869.47 in revenue and converted that into -2.14M in net income, yielding earnings per share of -0.03. EBITDA reached -2.22M, while operating income came in at -2.29M.

As of November 30, 2022, Bioasis Technologies Inc. holds 116,710.79 in cash and equivalents against 1.65M in total debt, resulting in a net debt position of 1.53M. Total book value stands at -2.01M, with working capital of -2.40M providing operational flexibility.

Bioasis Technologies Inc. produced -1.44M in operating cash flow over the twelve months ended November 30, 2022.

These figures cover the twelve months ended November 30, 2022. The operating margin of -1,141.16 and net profit margin of -1,067.59 provide insight into operational efficiency.

These figures cover the twelve months ended November 30, 2022. Free cash flow yield is negative at -15.36: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 4.18, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Bioasis Technologies Inc. shareholders.

As of November 30, 2022, Bioasis Technologies Inc. has an Altman Z-Score of -190.83, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.